Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The ATF7-NPFF readthrough protein is a predicted fusion protein arising from a *readthrough transcriptional event* between the neighboring ATF7 and NPFF genes on human chromosome 12[1][2][6]. This type of event results in a chimeric mRNA containing exons from both genes, which may code for a hybrid protein with sequence contributions from both parental genes. The biological function, protein expression, and clinical significance of the ATF7-NPFF readthrough protein have not been characterized, and there are no data supporting its involvement in disease, therapeutic targeting, or use as a biomarker. Its predicted functions, such as DNA-binding and transcription factor activity, are computationally inferred from the ATF7 portion, while the contribution of the NPFF segment is unknown[2][8].
No mechanisms of action documented; not an established drug target
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ATF7-NPFF readthrough protein (ATF7-NPFF).